adimin

Zoom shares surge premarket after video conferencing group tops Q4 estimates

-- Zoom Video Communications (NASDAQ:ZM) has reported fourth-quarter results that beat Wall Street estimates thanks to solid demand for its products during a time of increased hybrid working habits.   Shares in the video-conferencing software provider (NASDAQ:ZM), which also unveiled plans to buy back up to $1.5 billion of its Class A common stock, rose sharply in...

Read More

China approves Everest and Kezar lupus drug trial

SHANGHAI, China - Everest Medicines and Kezar Life Sciences (NASDAQ:KZR), Inc. have received approval from the Center for Drug Evaluation (CDE) of China\'s National Medical Products Administration (NMPA) to initiate a Phase 2b clinical trial for zetomipzomib, a treatment for lupus nephritis (LN), in China. The trial, named PALIZADE, will assess the efficacy and safety...

Read More